Screener
Vera Therapeutics VERA Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other liabilities, noncurrent | 1,864 | 1,919 |
| Total liabilities | 122,042 | 130,212 |
| Stockholders’ equity | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 71,730,090 and 71,267,429 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 72 | 71 |
| Additional paid-in capital | 1,381,678 | 1,364,529 |
| Accumulated other comprehensive (loss) income | (156) | 786 |
| Accumulated deficit | (881,897) | (760,865) |
| Total stockholders’ equity | 499,697 | 604,521 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's common stock?
- Vera Therapeutics (VERA) reported common stock of $72K in Q1 2026.
- How has Vera Therapeutics's common stock changed year-over-year?
- Vera Therapeutics's common stock increased by 12.5% year-over-year, from $64K to $72K.
- What is the long-term trend for Vera Therapeutics's common stock?
- Over 3 years (2022 to 2025), Vera Therapeutics's common stock has grown at a 36.4% compound annual growth rate (CAGR), from $28K to $71K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Vera Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude